Virginia Commonwealth University

Make it real.

Featured Researcher

Research Expertise and Focus

  • Translational Virology

Professional Highlights

Membership and Leadership

  • Principal Investigator, Richmond AIDS Consortium
  • Principal Investigator, Virginia HIV/AIDS Resource and Consultation Center
  • Member, HIV Medicine Association
  • Member, American Osteopathic Association

Fellowships

  • Infectious Diseases Society of America

Awards

  • Sigma Sigma Phi, National Osteopathic Medicine Honorary Fraternity, 1990
  • NFID/Astra Postdoctoral Fellowship Award in Herpesviral Research, 1995
  • NFID/NIAID Mentored Clinical Scientist Development Award, 1997-2002
  • VCU Department of Internal Medicine Faculty Award for Distinguished Research, 2006, 2009

Education and Training

  • Ph.D., Virginia Commonwealth University, Richmond, Va.
  • D.O., Ohio University, Athens, Ohio
  • B.S., Ohio State University, Columbus, Ohio

Selected Publications

Baker JV, Neuhaus J, Duprez D, Freiberg M, Bernardino JI, Badley AD, Nixon DE, Lundgren JD, Tracy RP, Neaton JD; INSIGHT SMART Study Group. HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction. J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):128-34. PMCID: PMC3360839

Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, Pedersen C, Ruxrungtham K, Lewin SR, Emery S, Neaton JD, Brenchley JM, Deeks SG, Sereti I, Douek DC; INSIGHT SMART Study Group. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011 Mar 15;203(6):780-90. PMCID: PMC3071127

Baker JV, Neuhaus J, Duprez D, Kuller LH, Tracy R, Belloso WH, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Nixon DE, Paton NI, Neaton JD; INSIGHT SMART Study Group. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):36-43. PMCID: PMC3005856

Nixon DE, Landay AL. Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS. 2010 Nov;5(6):498-503. PMCID: PMC3032605

Lifson AR, INSIGHT Cause of Death Writing Group, Belloso WH, Carey C, Davey RT, Duprez D, El-Sadr WM, Gatell JM, Gey DC, Hoy JF, Krum EA, Nelson R, Nixon DE, Paton N, Pedersen C, et al. Determination of the underlying cause of death in three multicenter international HIV clinical trials. HIV Clin Trials. 2008 May-Jun;9(3):177-185. PMCID: PMC2441601

Wang JB, Nixon DE, McVoy MA. Definition of the minimal cis-acting sequences necessary for genome maturation of the herpesvirus murine cytomegalovirus. J Virol. 2008 Mar;82(5):2394-2404. PMCID: PMC2258947

Masho SW, Wang CL, Nixon DE. Review of tenofovir-emtricitabine. Ther Clin Risk Manag. 2007 Dec;3(6):1097-1104. PMCID: PMC2387297

McVoy MA, Nixon DE. Impact of 2-bromo-5,6-dichloro-1-beta-D-ribofuranosyl benzimidazole riboside and inhibitors of DNA, RNA, and protein synthesis on human cytomegalovirus genome maturation. J Virol. 2005 Sep;79(17):11115-11127. PMCID: PMC1193602

Nixon DE, McVoy MA. Dramatic effects of 2-bromo-5,6-dichloro-1-beta-D-ribofuranosyl benzimidazole riboside on the genome structure, packaging, and egress of guinea pig cytomegalovirus. J Virol. 2004 Feb;78(4):1623-1635. PMCID: PMC369448

Nixon DE, McVoy MA. Terminally repeated sequences on a herpesvirus genome are deleted following circularization but are reconstituted by duplication during cleavage and packaging of concatemeric DNA. J Virol. 2002 Feb;76(4):2009-2013. PMCID: PMC135902